Compare NUTX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | ORIC |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2009 | 2020 |
| Metric | NUTX | ORIC |
|---|---|---|
| Price | $208.84 | $12.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $252.50 | $19.73 |
| AVG Volume (30 Days) | 117.6K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.93 | ★ 19.67 |
| EPS | ★ 15.87 | N/A |
| Revenue | ★ $875,257,000.00 | N/A |
| Revenue This Year | $6.12 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | $13.50 | ★ N/A |
| Revenue Growth | ★ 82.36 | N/A |
| 52 Week Low | $83.99 | $7.23 |
| 52 Week High | $224.28 | $14.93 |
| Indicator | NUTX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 49.83 |
| Support Level | $142.71 | $10.67 |
| Resistance Level | N/A | $13.04 |
| Average True Range (ATR) | 10.19 | 0.57 |
| MACD | 1.29 | -0.08 |
| Stochastic Oscillator | 72.61 | 51.80 |
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.